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OBJECTIVE: Little is known about metabolic factors in cirrhotic patients in China. Therefore, we aimed to quantify
the prevalence of both metabolic factors and non-alcoholic steatohepatitis-related liver cirrhosis in China.
METHODS: The medical records of 1,582 patients diagnosed with liver cirrhosis from June 2003 to July 2013 at
Daping Hospital (Chongqing, China) were retrospectively reviewed through a computer-generated search.
RESULTS: Serum hepatitis B virus surface antigen was present in 1,083 (68.5%) patients, and hepatitis B was found
to be the only etiological factor in 938 (59.3%) of all patients. Obesity, diabetes mellitus, and arterial hypertension
were observed in 229 (14.5%), 159 (10.1%), and 129 (8.2%) patients, respectively. From 2012-2013, the proportion
of non-alcoholic steatohepatitis-related liver cirrhosis increased to 3.2%, whereas the average proportion of non-
alcoholic steatohepatitis-related liver cirrhosis in the previous ten years was 1.9%. The incidence of hepatocellular
carcinoma was much higher in males than in females (6.3% vs. 3.7%, respectively, p=0.036). Obesity and diabetes
mellitus did not significantly increase the incidence of hepatocellular carcinoma in the whole cirrhotic group. The
presence of hepatitis B virus was the only risk factor for hepatocellular carcinoma in cirrhotic patients (po0.001).
CONCLUSIONS: Although hepatitis B virus remains the main etiology of liver cirrhosis in China, steatohepatitis-
related liver cirrhosis is increasing in frequency. Hepatitis B virus was the sole significant risk factor for
hepatocellular carcinoma in the whole cirrhotic group in the present study, in contrast to obesity and diabetes
mellitus, for which only a trend of increased hepatocellular carcinoma was found.
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The main etiology of liver cirrhosis (LC) in China is
hepatitis B virus (HBV) infection (1). However, the changing
proportions of the various potential etiological factors over
the last 10 years remain poorly documented, especially the
presence of metabolic characteristics such as obesity (or
increased body mass index [BMI]), diabetes mellitus (DM),
hypertension and alcoholism. In Western countries, non-
alcoholic steatohepatitis (NASH)-related cirrhosis is increas-
ingly considered as a major causal factor of cirrhosis.
Moreover, hepatocellular carcinoma (HCC) is related to
NASH-related cirrhosis in Germany (2). For several possible
reasons, few data exist regarding NASH-related LC in China.
First, NASH-related cirrhosis is diagnosed by exclusion, and
ruling out all other possible causes is difficult. Second, the
histological characteristic features of non-alcoholic fatty liver
disease (NAFLD) such as fatty infiltration tend to be lost in
NASH-related cirrhosis (3). Third, there is a lack of strict
criteria for diagnosing NASH-related cirrhosis. According to
one nationwide Japanese survey, 2.1% of cirrhosis cases were
attributable to NASH-related cirrhosis based on the research-
ers’ own criteria, which mainly diagnosed NASH-related
cirrhosis as cryptogenic cirrhosis associated with obesity
(BMI over 25), DM or metabolic syndrome (Met-s) (4).
If appropriate criteria are used, NASH-related cirrhosis
may account for two thirds of cases currently labeled as
cryptogenic cirrhosis (3). Herein, we retrospectively analyzed
etiological factors in LC in patients admitted to our hospital
over the past 10 years to evaluate the proportion and time
trend of NASH-related LC, with special emphasis on the
factors favoring HCC development.
’ PATIENTS AND METHODS
The medical records of patients diagnosed with LC from
June 2003 to July 2013 at Daping Hospital (Chongqing,
China) were retrospectively reviewed through a computer-
generated search. The study included 1,582 patients.DOI: 10.6061/clinics/2015(08)06
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LC was diagnosed based on clinical symptoms, imaging
data, and/or histological findings (only 41 patients had a
liver biopsy in the present series). Classical criteria for each
etiology potentially involved in LC were applied to
categorize cirrhotic patients. For NASH-related LC, we
adopted the following criteria. First, all NASH-related LC
had to be cryptogenic LC and had to be coupled with alcohol
consumption of less than 20 grams per day. Second, the BMI
of each patient had to be over 25, with or without DM or
Met-s; this was slightly different from the Japanese criteria
(4), which did not include obesity as a necessary criterion. If
the above two criteria were met, then the patient was
clinically suspected of having NASH-related LC. Further-
more, if histological findings such as micronodular cirrhosis,
perisinusoidal fibrosis or fatty changes were found, then the
patient was histologically diagnosed with NASH-related LC.
Among the 30 patients diagnosed with NASH-related LC,
only one patient was histologically diagnosed with NASH-
related LC by liver biopsy.
Clinical information (age, gender, alcohol consumption,
virus infection, hepatic complications) was also collected for
all patients with LC. Metabolic risk factors such as obesity,
DM and arterial hypertension were systematically collected
based on the diagnostic history. The Child-Pugh criteria were
used to grade cirrhosis.
Statistical analysis
The dichotomous data and continuous data were analyzed
by the chi-square test and Student’s t test, respectively, using
Statistical Package for the Social Sciences (SPSS, version 15.0;
Chicago, IL, USA). Logistic regression was used to analyze
the selected risk factors for HCC. When examining the
differences between males and females, Fisher’s exact test
and the Mann-Whitney U test were also used. A p-value of
o0.05 was considered statistically significant.
’ RESULTS
Etiology of LC
A total of 1,582 patients diagnosed with LC from 2003-
2013 were included in this retrospective study. A total of
1,097 (69.4%) patients were male, 485 (30.6%) were female,
and 87 (5.5%) were diagnosed with HCC during
hospitalization.
In our study, 14 etiological categories were set for LC
(Table 1). The most common etiology was HBV; hepatitis B
surface antigen (HBs Ag) was present in the sera of 1,083
(68.5%) patients. HBV was found to be the only etiological
factor in 938 (59.3%) patients. Hepatitis C virus (HCV)
accounted only for 1.8% of cases (1.0% of patients had HCV
alone, 0.5% had HCV combined with HBV, and 0.3% had
HCV combined with alcohol abuse). Hepatitis E virus
combined with HBV was found in only two patients. In
total, 298 (18.7%) patients had a history of alcohol abuse (135
of them also had HBV infection, and 5 patients also had HCV
infection; alcohol was the dominant factor in 158 patients).
There were 32 patients with autoimmune hepatitis (AIH), 69
patients with primary biliary cirrhosis (PBC), 4 patients
with AIH combined with PBC, and 6 patients with
Wilson’s disease. For NASH-related LC, 30 patients (1.9%)
met our criteria. Thirteen patients had other identi-
fied etiologies, including intra-hepatic bile-duct stones
(9 patients), Budd-Chiari syndrome (2 patients), parasitic
infection (1 patient), and veno-occlusive disease (1 patient).
The remaining 167 patients had cryptogenic LC, as defined by
the absence of identified causes, including NASH-related LC
criteria.
Etiological differences between males and females
HBV was clearly the main etiology in both males and
females (59.8% vs. 57.9%, respectively, p40.05) (Figure 1).
The percentages of patients with alcohol abuse, HBV plus
alcohol abuse, and HCV plus alcohol abuse were higher in
males vs. females (11.2% vs. 1.0%, po0.01; 12.2% vs. 0.2%,
po0.01; and 0.5% vs. 0%, po0.01, respectively). However,
the percentages of AIH and PBC were much higher in
females vs. males (4.9% vs. 0.7%, po0.01; 12.6% vs. 0.7%,
po0.01, respectively). No difference between males and
females existed for NASH-related LC (1.7% vs. 2.3%,
respectively, p=0.47).
Time trend of metabolic factors and HCC in
cirrhotic patients
The metabolic information recorded during the periods
from 2003-2008 and 2008-2013 was compared (Table 2).
Whereas the total number of patients from 2008-2013 was
two times higher than the number in the period from 2003-
2008 (1,091 and 491, respectively), no significant differences
were noted in terms of age, sex ratio, or BMI between the two
time periods. Trends of increased obesity, DM, hypertension
and HBs Ag positivity were observed in the second five-year
period. In contrast, the proportion of HCC significantly
decreased in the period from 2008-2013 (4.7% vs. 7.3%,
p=0.033) (Table 2).
NASH-related LC
Among the total of 197 patients with cryptogenic LC, 30
patients met our criteria for NASH-related LC. As shown in
Figure 2, the proportion of NASH-related LC increased in
the last two years of the study to 3.2%, compared with 1.9%
for the whole study period.
Table 1 - Etiologies of liver cirrhosis from 2003-2013.
Category No. of patients (%)
HBV alone 938 (59.3)














HBV alone: hepatitis B virus was the only etiological factor for cirrhosis;
HCV alone: hepatitis C virus was the only etiological factor for cirrhosis;
HBV/HCV: hepatitis B virus combined with hepatitis C virus; HBV/HEV: hepa-
titis B virus combined with hepatitis E virus; HBV/Alcohol: hepatitis B virus
combined with alcohol abuse; HCV/Alcohol: hepatitis C virus combined
with alcohol abuse; AIH: autoimmune hepatitis; PBC: primary biliary cir-
rhosis; AIH/PBC: autoimmune hepatitis combined with primary biliary
cirrhosis.
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Among the 30 patients with NASH-related LC, 19 patients
were men, and 11 were women (no statistical significance).
Ascites and upper gastrointestinal bleeding (UGB) were the
main complications in patients with NASH-related LC, and the
complication rate of both ascites and UGBwas higher in women,
but the difference was not significant. For Child-Pugh grading of
NASH-related LC, the rate of Child Awas lower in women than
in men, but the difference was not significant. HCC was not
found in women or men with NASH-related LC. (Table 3).
Selected risk factors for HCC
Among the 87 patients with HCC, 69 patients were men,
and 18 patients were women. As shown in Table 4, only the
sex ratio (male to female) and HBs Ag positivity rate were
significantly increased in HCC patients compared with non-
HCC patients (po0.05) by univariate analysis. Metabolic
factors, which included obesity, DM, and hypertension, were
not significantly different between men and women. HBs Ag
positivity was the sole risk factor for HCC in cirrhotic
patients (po0.001) in a multivariate analysis. Obesity and
DM did not increase the HCC incidence in the whole
cirrhotic group (5.7% vs. 5.5%, respectively, p=0.862; 5.0% vs.
5.6%, respectively, p=0.849). However, among patients with
cirrhosis induced only by HBV, a trend of increased rates of
HCC in obese and DM patients was found (8.4% vs. 6.5%,
respectively, p=0.436; 7.1% vs. 6.7%, respectively, p=0.589).
’ DISCUSSION
In our study, HBV remained the main etiological factor
(68.5%) for LC in China, whereas HCV was by far the most
frequent cause of cirrhosis (60.9%) according to a nationwide
survey in Japan (4). HCV accounted for only 1.8% of our
cirrhotic patients. Alcoholic liver disease and hepatitis C are
the most common causes of cirrhosis in the Western world,
whereas hepatitis B is the prevailing cause in most parts of
Asia and sub-Saharan Africa (5). For example, in the United
Kingdom (6), a total of 3,360 incident cases of cirrhosis in
patients aged 25 or older were diagnosed with LC between
1992 and 2001, and 35.9% of these cases were induced by
alcohol, whereas only 5.4% were induced by viral hepatitis.
In the USA, 7% of cirrhosis cases were attributable to HBV,
and 27% were to HCV from 1989-2000(7). Globally, 57% of
cirrhosis cases were attributable to either HBV (30%) or HCV
(27%) (7). In China, as reported in our study, 59.3% of
cirrhosis cases were only related to HBV infection. In a large
community-based study in eastern China (8), a total of
149,175 individuals were investigated in 60 communities in
three counties in Jiangsu province from 2011-2012. Of these
subjects, 1,175 (0.79%, 95% confidence interval (CI) 0.74-0.83)
were anti-HCV antibody positive. The prevalence was even
lower in children (0.09%, 95% CI 0.04-0.17). A seroepide-
miological survey of HCV conducted in 2007 revealed a
lower rate of anti-HCV antibody positivity (0.80%) in
Chongqing, Southwest China than in the general population
(9). Thus, the prevalence of hepatitis C as a cause of LC is low
in Chongqing, China.
The difference between Asia or sub-Saharan Africa and the
Western world may be related to the wide implementation of
HBV programs, which has not been financially possible in
numerous developing countries. In 1992, the World Health
Organization (WHO) recommended that all countries
include a hepatitis B vaccine in their routine infant
immunization programs. As of 2003, the WHO/UNICEF
estimated 42% hepatitis B vaccination coverage in the global
birth cohort (7). In China, the HBV infection prevalence
decreased from 9.7% (in 1992) to 7.2% (in 2006) after the
introduction of a universal HBV vaccination program in 1988
(10). However, in our study, we did not observe the
theoretically expected decrease in the development of HBV-
induced LC, possibly because HBV infection was present
Figure 1 - Difference in etiologies between males and females.
Table 2 - Clinical characteristics of cirrhotic patients.
Total 2003–2008 2008–2013 p-value#
Age (years) 52.8±12.8 52.3±12.8 52.7±12.7 0.519
Female 485 147 338 0.678
Male 1,097 344 753
Male/female 2.26 2.34 2.23
BMI (Mean ± SD) 22.1±3.3 22.1±3.5 22.1±3.2 0.894
Obesity (%) 229 (14.5) 71 (14.5) 158 (14.5) 0.991
DM (%) 159 (10.1) 44 (8.9) 115 (10.5) 0.334
Hypertension (%) 129 (8.2) 33 (6.7) 96 (8.8) 0.162
HBs Ag+ (%) 1,083 (68.5) 325 (66.2) 758 (69.5) 0.193
HCC (%) 87 (5.5) 36 (7.3) 51 (4.7) 0.033
Number of patients 1,582 491 1,091
BMI: body mass index; DM: diabetes mellitus; HBS Ag+: hepatitis B virus
surface antigen positive; HCC: hepatocellular carcinoma.
#p-value comparing 2003–2008 with 2008–2013.
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prior to the start of the vaccination campaign; the develop-
ment of cirrhosis usually requires a long period of time (11).
Nevertheless, the efficacy of the Chinese HBV immunization
program is indicated by the decreased prevalence of HBV
carrier status to 2.1% among all children and to 1.0% among
those born after 1999, together with the presence of anti-HBs
antibodies (1,12). Therefore, it is likely that HBV-related
etiology of Chinese LC will be significantly reduced in the
future.
In Western countries, NAFLD is now considered to be the
most common cause of chronic liver disease, with 20-30% of
the total population presenting with NAFLD (13,14). In
China, NAFLD affects approximately 15% of adults and is
present in 68.5% of obese children (15, 16). The proportion of
NASH-related LC (1.9%) in our study was similar to that in
Japan (2.1%) (4). However, our study was retrospective and
may not represent the incidence of LC in the general
population. In our study, an increasing frequency was noted
over the ten years covered by the study; this trend is likely to
result in a significant increase in patients with NASH-related
LC in the future.
A limitation of the current study, especially in the context
of a retrospective study, is that diagnosing LC related to
NASH requires a BMI higher than 25. However, our criteria
were based on those adopted by the Japanese nationwide
study, with the difference that a BMI higher than 25 was
necessary but not the sole criterion to consider cryptogenic
cirrhosis as NASH-related cirrhosis because abnormal
glucose metabolism, arterial hypertension and high trigly-
ceride levels in the patients were also considered. Although
NASH can be found in lean patients, the identification of
metabolic features or performance of a liver biopsy is
required for an accurate diagnosis. Due to the retrospective
nature of our study, we could not document the number of
lean patients; thus, we adopted a BMI higher than 25 as a
necessary criterion. Notably, a liver biopsy may lack relevant
metabolic features when cirrhosis is present and therefore
may not always contribute to determining the etiology.
Although we considered obesity and DM in our study
when diagnosing NASH-related LC, we did not find
significant differences in the proportions of obesity, DM
and hypertension when comparing the 2003-2008 and 2008-
2013 time periods.
Several studies have reported that Met-s (obesity or DM)
not only promotes the development of LC but also increases
the risk of HCC (17-19). In China, obesity has become an
important health problem because the prevalence of obesity
in adults, which was 7.1% in 2002, has increased by 97.2%
since 1992 (20,21). In children, a dramatic increase in obesity
has been observed, with a two- to three-fold increase in
Beijing and Shanghai between 1985 and 1995. In addition,
the prevalence of overweight and obese children approached
29% in 2000 in 7- to 12-year-old boys and 15-17% in girls (21).
A 2013 study from Tianjing, China, also found that the
prevalence of obesity in children under 7 years old
approached 8.2% (22). These data illustrate the rapid
development of obesity in both adults and children. In the
USA, data from the 2009-2010 National Health and Nutrition
Examination Survey reveal that 36% of Americans are obese
and that 30% of the general adult population may have
NAFLD (23). In the USA, the yearly cumulative HCC
incidence in NASH-related LC was 2.6%, compared with
4.0% among patients with HCV-related cirrhosis, over an
average follow-up period of 3.2 years (24). Therefore, the
rapid development of obesity in China could be contributing
to an increase in NAFLD, leading to the increased prevalence
of NASH-related LC shown in our study. The importance of
obesity in the natural history of NASH-related LC explains
Figure 2 - Time trend of NASH-related LC over the ten year period
from 2003-2013.
Table 3 - Clinical characteristics of NASH-related LC.
Total Female (F) Male (M) p-value (F vs. M)
Number of patients 30 11 19
Age (years) 57.7±14.1 60.6±12.4 55.9±15.0 0.388a
BMI (Kg/m2) 27.2±2.1 27.2±2.2 27.2±2.0 0.965a
Arterial hypertension (%) 11 (36.7) 6 (54.6) 5 (26.3) 0.238b
DM (%) 8 (26.7) 1 (9.1) 7 (36.8) 0.199b
Complications
Ascites (%) 12 (40.0) 5 (45.5) 7 (36.8) 0.712b
HCC (%) 0 (0) 0 (0) 0 (0)
UGB (%) 6 (20.0) 3 (27.3) 3 (15.8) 0.641b
HRS (%) 0 (0) 0 (0) 0 (0)
HE (%) 0 (0) 0 (0) 0 (0)
Child-Pugh grading 0.308c
A (%) 16 (53.3) 5 (45.5) 11 (57.9)
B (%) 12 (40.0) 4 (36.4) 8 (42.1)
C (%) 2 (6.7) 2 (18.2) 0 (0)
BMI: body mass index; DM: diabetes mellitus; HCC: hepatocellular carcinoma; UGB: upper gastrointestinal bleeding; HRS: hepatorenal syndrome; HE: hepatic
encephalopathy.
p-value determined by a: Student’s t test; b: Fisher’s exact test; c: the Mann-Whitney U test.
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why we decided to integrate this risk factor as a necessary
criterion for diagnosing NASH-related LC in our study.
Although the increases in NASH-related LC and obesity
may lead to a higher incidence of HCC, we unexpectedly
found that the HCC incidence was significantly lower in the
time period from 2008-2013 than in the period from 2003-
2005. Another recent study, which used data from the Cancer
Registration Database records in Shanghai, China, also noted
a decreasing HCC incidence (25). This study additionally
found that the age-standardized incidence rates for each year
and the age-standardized mortality rates decreased from
2006-2008 and that the incidence and mortality rates
increased with age. The incidence and mortality rates of
primary liver cancer were relatively higher in the suburbs
than in urban areas and were also higher in males than in
females. Additionally, a study from Taiwan found that male
gender was a risk factor for HCC, which is in accordance
with our results based on univariate analysis. However, DM
and obesity were not associated with HCC in areas where
either HBV or HCV was endemic (26). In our study, obesity
and DMwere not associated with HCC in the whole cirrhotic
population, in accordance with the Taiwanese study. How-
ever, when considering only the HBV-related cirrhotic
subgroup, we observed a statistically insignificant trend of
increased HCC in patients who were obese or diabetic. The
prevalence of NAFLD-related HCC is rising worldwide:
4-22% of HCC cases in Western countries are now attributed
to NAFLD (13). Additionally, 10-75% of cases of NAFLD-
related HCC occur in patients without cirrhosis (27,28).
A higher BMI in childhood increases the risk of primary liver
cancer in adults (29). In our study, HCC was not found in
patients with NASH-related LC, whereas HCC was present
in 31.5% of NASH-related LC cases in the Japanese
nationwide study (4). A study from England found that
NAFLD accounted for 41 (34.8%) cases of HCC in 2010 (30).
Another study on HCC from Germany also found an
increasing proportion of NASH in HCC patients (2). With
the promotion of an HBV vaccination program and the
improvement of economic development, this type of time
trend may also occur in China. Therefore, we should expand
our attention from patients with cirrhosis caused by chronic
viral hepatitis to those with cirrhosis induced by NASH in
the future. Additionally, patients with NASH-related LC
must be followed in the coming decades, paying special
attention to the effects in obese children, as the vaccination
program has protected them from HBV.
For NASH-related LC, we found that female patients were
older than males and that the rates of complications and
Child-Pugh grade C tended to be higher in women, which is
in accordance with the Japanese nationwide study (4).
However, the difference in our study was not significant,
possibly due to the small sample size. The epidemiological
study in Japan observed a higher NAFLD prevalence in men
than in women. However, in contrast to men, NAFLD
increased with age in women, showing a higher prevalence
among women aged 40-49 years and after menopause (31).
Aging is considered as a risk factor for NAFLD in pre-
menopausal women (32). Our study showed an average age
of 60 years for women who developed NASH-related LC,
indicating that they were menopausal women. Because
estradiol has been reported to attenuate hepatic stellate cell
activation and therefore decrease the fibrotic process (33),
estradiol diminution after menopause might contribute to
the development of NASH-related cirrhosis.
Our study has several limitations. First, because the study
was retrospective, it was not possible to collect certain
Table 4 - Selected risk factors for HCC.
Variable Control HCC Univariate analysis Multivariate analysis
N=1,495 (%) N=87 (%) OR (95% CI) p-value OR (95% CI) p-value
Age
o65 1,227 (94.6) 70 (5.4) 0.93 (0.52-1.64) 0.796
X65 268 (94.0) 17 (5.9)
Sex
Female 468 (96.3) 18 (3.7) 1.81 (1.04-3.14) 0.036
Male 1,027 (93.7) 69 (6.3)
Obesity
Obese 216 (94.3) 13 (5.7) 1.06 (0.58-1.96) 0.862
Non-obese 1,279 (94.5) 74 (5.5)
Hypertension
Hypertensive 123 (95.3) 6 (4.6) 0.90 (0.37-2.21) 0.825
Non-hypertensive 1,362 (94.4) 81 (5.6)
DM
Diabetic 151 (95.0) 8 (5.0) 0.93 (0.43-1.99) 0.849
Non-diabetic 1,344 (94.5) 79 (5.6)
HBs Ag
HBs Ag positive 1,008 (93.1) 75 (6.9) 2.64 (1.01-6.92) 0.049 3.35 (1.76-6.36) 0.000
HBs Ag negative 487 (98.6) 7 (1.4)
Hepatitis B*
HBV+obesity 121 (91.7) 11 (8.4) 1.31 (0.66-2.58) 0.436
HBV+non-obesity 754 (93.6) 52 (6.5)
HBV+DM 65 (92.8) 5 (7.1) 1.27 (0.53-3.07) 0.589
HBV+non-DM 810 (93.3) 58 (6.7)
Alcohol#
HBV+alcohol abuse 123 (91.1) 12 (8.9) 0.74 (0.39-1.42) 0.364
HBV+no alcohol abuse 885 (93.4) 63 (6.7)
*Cirrhotic patients with chronic liver disease caused only by HBV infection (938 patients).
#Alcohol abuse in cirrhotic patients with HBs Ag positivity (1,083 patients).
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important metabolic parameters such as blood glucose for all
cirrhotic patients, which may have led to underestimation of
the rate of DM in LC. Second, histological data were rarely
obtained for our patients, which confined the diagnosis of
NASH-related cirrhosis to clinical, biochemical, and imaging
data. However, it should be recalled that when cirrhosis is
histologically present, the etiological features may disappear,
so a liver biopsy may not be able to ascertain NASH-related
cirrhosis. Third, the relatively small number of NASH-
related LC cases might explain the absence of significant
differences when considering important risk factors reported
in other studies. Finally, the history of NAFLD and the
duration of obesity or DM could not be obtained from the
database.
In conclusion, HBV remains the main etiology of LC in
China. However, NASH-related LC has clearly increased in
frequency in recent years. Further studies are warranted to
evaluate the exact importance of obesity and diabetes in
HCC development in the overall cirrhotic population.
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